glp 1 blood brain barrier Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation Glucagon-like peptide-1 (GLP-1), released from

High potassium levels (hyperkalemia) or low potassium levels (hypokalemia)

However, the cellular stress of the upstream events, i.e., reactive metabolite formation, GSH depletion, and protein adducts formation, is still present and this stress may trigger apoptosis in a limited number of cells (Figure 1)

IGF-1 Upregulation Downstream Anabolic Signaling Both peptides indirectly stimulate insulin-like growth factor-1 (IGF-1) production through sustained growth hormone elevation: Growth hormone binds to hepatic GH receptors activating JAK-STAT signaling pathways Increased transcription of IGF-1 gene in liver tissue Elevated plasma IGF-1 levels mediate anabolic effects in muscle, bone, and adipose tissue IGF-1 provides negative feedback regulation preventing excessive growth hormone secretion Studies report IGF-1 increases of 1.5- to 3-fold for 9-11 days following CJC-1295 administration, with the ipamorelin combination providing more sustained elevation

Environ Toxicol 35(6):683

doi: 10.1042/bj2120835 35 LasnierECoudray-LucasCLe BoucherJJardelACynoberL

Birla, A., Satia, M., Shah, R., Pai, A., Srivastava, S., & Langade, Deepak